| A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies RD Harvey, TK Owonikoko, CM Lewis, A Akintayo, Z Chen, M Tighiouart, ... British journal of cancer 108 (4), 762-765, 2013 | 25 | 2013 |
| Race-, age-, and gender-based characteristics and toxicities of targeted therapies on phase I trials TK Owonikoko, AK Busari, S Kim, Z Chen, A Akintayo, C Lewis, ... Oncology 95 (3), 138-146, 2018 | 5 | 2018 |
| A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies. TK Owonikoko, RD Harvey, JS Kauh, CM Lewis, MS Hossain, ... Journal of Clinical Oncology 30 (15_suppl), 2576-2576, 2012 | 3 | 2012 |
| A phase 1 and pharmacokinetic study of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel in patients with advanced solid tumor malignancies RD Harvey, CM Lewis, JS Kauh, TK Owonikoko, A Akintayo, M Karol, ... Poster presented at: European Society of Medical Oncology at the European …, 2011 | 1 | 2011 |
| 1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid … RD Harvey, CM Lewis, JS Kauh, TK Owonikoko, A Akintayo, M Karol, ... European Journal of Cancer, S153, 2011 | | 2011 |
